Phapros Tbk PT
PT Phapros Tbk, together with its subsidiaries, operates in the pharmaceutical industry in Indonesia. The company operates through Ethical; Over the Counter (OTC) Drugs; Generic Drugs Bearing (OCB); and Toll-in segments. It offers OTC drugs, including Antimo Anak, Antimo tablet, Livron B Plex, X-Gra, Becefort Sirop and tablet, Noza, Febrinex, Betafort suspensi, and Hemorogard. The company also pr… Read more
Phapros Tbk PT (PEHA) - Total Liabilities
Latest total liabilities as of June 2025: Rp1.06 Trillion IDR
Based on the latest financial reports, Phapros Tbk PT (PEHA) has total liabilities worth Rp1.06 Trillion IDR as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Phapros Tbk PT - Total Liabilities Trend (2011–2024)
This chart illustrates how Phapros Tbk PT's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Phapros Tbk PT Competitors by Total Liabilities
The table below lists competitors of Phapros Tbk PT ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Utility Business Alliance PCL
BK:UBA
|
Thailand | ฿80.28 Million |
|
Great Divide Mining Ltd
AU:GDM
|
Australia | AU$424.04K |
|
Pharmsville Co. Ltd
KQ:318010
|
Korea | ₩2.58 Billion |
|
Crown Lifters Limited
NSE:CROWN
|
India | ₹1.19 Billion |
|
Timberwell Bhd
KLSE:7854
|
Malaysia | RM14.94 Million |
|
Free Flow Inc
OTCQB:FFLO
|
USA | $2.08 Million |
|
Blue Label Telecoms Ltd
JSE:BLU
|
South Africa | ZAC12.13 Billion |
|
SAG Holdings Limited
NASDAQ:SAG
|
USA | $30.72 Million |
Liability Composition Analysis (2011–2024)
This chart breaks down Phapros Tbk PT's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.30 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.78 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.73 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Phapros Tbk PT's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Phapros Tbk PT (2011–2024)
The table below shows the annual total liabilities of Phapros Tbk PT from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Rp1.04 Trillion | +4.15% |
| 2023-12-31 | Rp995.56 Billion | -3.76% |
| 2022-12-31 | Rp1.03 Trillion | -5.75% |
| 2021-12-31 | Rp1.10 Trillion | -6.60% |
| 2020-12-31 | Rp1.18 Trillion | -7.84% |
| 2019-12-31 | Rp1.28 Trillion | +18.19% |
| 2018-12-31 | Rp1.08 Trillion | +127.35% |
| 2017-12-31 | Rp474.55 Billion | +81.67% |
| 2016-12-31 | Rp261.21 Billion | +13.11% |
| 2015-12-31 | Rp230.93 Billion | +0.48% |
| 2014-12-31 | Rp229.84 Billion | -8.68% |
| 2013-12-31 | Rp251.69 Billion | +37.52% |
| 2012-12-31 | Rp183.02 Billion | +48.29% |
| 2011-12-31 | Rp123.42 Billion | -- |